Menu
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Buy Currently
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Sample Portfolio
Sample Portfolio Analysis
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Account Requirements
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
Municipal Bond Presentation
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Normally Buy
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF® Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Latest News about LILLY DRN
Recent news which mentions LILLY DRN
< Previous
1
2
3
Next >
Eli Lilly to release late-stage data on next-generation weight loss drug retatrutide in 2025, earlier than expected
February 06, 2025
Tags
Novo Nordisk A/S
Breaking News: Business
Business
From
CNBC.com News
Eli Lilly posts mixed quarter even as demand for weight loss, diabetes drugs soars
February 06, 2025
Tags
Pharmaceuticals
US: News
Business News
From
CNBC.com News
Novo Nordisk CEO says he's confident about Wegovy supply, next-generation weight loss drugs
February 05, 2025
Tags
Novo Nordisk A/S
Biotech and Pharmaceuticals
Earnings
From
CNBC.com News
Novo Nordisk posts net profit beat as Wegovy sales jump 107% in fourth quarter
February 05, 2025
Tags
Biotech and Pharmaceuticals
Breaking News: Europe
Business
From
CNBC.com News
Healthy Returns: Why people quit weight loss, diabetes drugs within one year
February 04, 2025
Tags
Novo Nordisk A/S
Biotech and Pharmaceuticals
Science
From
CNBC.com News
5 things to know before the stock market opens Monday
February 03, 2025
Tags
International trade
Constellation Brands Inc
General Motors Co
From
CNBC.com News
Reid Hoffman enters 'wondrous and terrifying' world of health care with latest AI startup
February 02, 2025
Tags
Technology
Airbnb Inc
Merck & Co Inc
From
CNBC.com News
Jim Cramer's week ahead: Earnings from Amazon, Alphabet, Eli Lilly, Palantir
January 31, 2025
Tags
Novo Nordisk A/S
Bristol/Myers Squibb Co
Palantir Technologies Inc
From
CNBC.com News
FDA approves Novo Nordisk’s diabetes drug Ozempic for chronic kidney disease, expanding its use
January 28, 2025
Tags
Science
Biotech and Pharmaceuticals
Novo Nordisk A/S
From
CNBC.com News
Food-as-medicine startups hope Kennedy, if confirmed as HHS secretary, will boost their businesses
January 28, 2025
Tags
Nutrition
Novo Nordisk A/S
Venture capital
From
CNBC.com News
Pharma is hopeful about Trump's second term — here's what to expect for drugmakers
January 26, 2025
Tags
Pfizer Inc
US: News
Companies
From
CNBC.com News
'Miracle' drug innovation could see a new Wegovy launch every couple of years, Larry Summer says
January 21, 2025
Tags
Pharmaceuticals
Banks
World Economy
From
CNBC.com News
GLP-1s and Brian Thompson’s killing loom large at top health-care conference
January 18, 2025
Tags
Novo Nordisk A/S
Dexcom Inc
AI / Artificial Intelligence
From
CNBC.com News
Ozempic is in the next round of Medicare drug price negotiations. See the full list of 15 medications
January 17, 2025
Tags
Abbvie Inc
LILLY DRN
Business News
From
CNBC.com News
Bristol Myers Squibb says Alzheimer's is the biggest market for new schizophrenia drug
January 15, 2025
Tags
Health care industry
Biotechnology
Companies
From
CNBC.com News
Jim Cramer says he supports healthcare stocks for their long-term value
January 14, 2025
Tags
LILLY DRN
Stock markets
Regeneron Pharmaceuticals Inc
From
CNBC.com News
Healthy Returns: From Eli Lilly to Amazon, here are the latest health-care deals
January 14, 2025
Tags
Biotech and Pharmaceuticals
Moderna Inc
Teladoc Health Inc
From
CNBC.com News
Eli Lilly shares drop as drugmaker cuts revenue guidance on weight loss drug demand
January 14, 2025
Tags
Business
Breaking News: Business
Biotech and Pharmaceuticals
From
CNBC.com News
Eli Lilly CEO expects new weight loss pill to be approved next year
January 13, 2025
Tags
Business News
Health care industry
LILLY DRN
From
CNBC.com News
High-cost weight loss drugs are sending employers to nutrition counseling in a boost for startups
January 10, 2025
Tags
Health care industry
LILLY DRN
Health & Science
From
CNBC.com News
Medicare can now cover Eli Lilly’s Zepbound for sleep apnea, CMS says
January 08, 2025
Tags
US: News
Companies
Biotechnology
From
CNBC.com News
Healthy Returns: The FDA approved fewer new drugs in 2024 — but some big ones hit the market
January 08, 2025
Tags
Iovance Biotherapeutics Inc
Merck & Co Inc
Health & Science
From
CNBC.com News
Cramer's Lightning Round: Uber is a buy
January 02, 2025
Tags
stocks
Lazard Ltd
PENN Entertainment Inc
From
CNBC.com News
FDA says the Zepbound shortage is over. Here’s what that means for compounding pharmacies, patients who used off-brand versions
December 24, 2024
Tags
Health care policy
LILLY DRN
Health & Science
From
CNBC.com News
FDA approves Eli Lilly's weight loss drug Zepbound for sleep apnea, expanding use in U.S.
December 20, 2024
Tags
Companies
Health & Science
Biotechnology
From
CNBC.com News
5 things to know before the stock market opens Friday
December 20, 2024
Tags
Markets
5 Things to Know
Business
From
CNBC.com News
FDA says Eli Lilly's weight loss drug Zepbound is no longer in shortage
December 19, 2024
Tags
US: News
Companies
Biotechnology
From
CNBC.com News
Healthy Returns: A huge deal to boost Novo Nordisk's manufacturing is one step closer to closing
December 11, 2024
Tags
Roche Holding AG
Novo Nordisk A/S
Biotech and Pharmaceuticals
From
CNBC.com News
Ro to offer lower-price vials of weight loss drug Zepbound by teaming up with Eli Lilly
December 11, 2024
Tags
Biotech and Pharmaceuticals
Amazon/com Inc
Business
From
CNBC.com News
The weight-loss drug boom has become one of the internet's biggest scams
December 08, 2024
Tags
Crime
Technology
Cyber Report
From
CNBC.com News
< Previous
1
2
3
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.